<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466543</url>
  </required_header>
  <id_info>
    <org_study_id>SMC 2011-05-042</org_study_id>
    <nct_id>NCT01466543</nct_id>
  </id_info>
  <brief_title>Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity</brief_title>
  <acronym>SMCZN01</acronym>
  <official_title>Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Zydena (Udenafil) has effect on cerebral
      blood flow and peripheral blood viscosity in normal and subcortical vascular cognitive
      impairment subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Udenafil is a newly developed selective phosphodiesterase type 5 inhibitor (PDE5i). Since
      PDE5i is known to relax smooth muscle cells, it is suggested that PDE5i may dilate cerebral
      vessels and lead to an increase in cerebral blood flow. The main mechanism of subcortical
      vascular cognitive impairment are hypoperfusion of the brain. Therefore, in this study, the
      investigators will investigate whether Udenafil can increase cerebral blood flow and also
      lower peripheral blood viscosity in normal and subcortical vascular cognitive impairment
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral blood flow</measure>
    <time_frame>One hour after the administration of the medication</time_frame>
    <description>Measured by Near-infrared spectroscopy (NIRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood viscosity</measure>
    <time_frame>One hour after the administration of the medication</time_frame>
    <description>Measured from whole blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Vascular Dementia</condition>
  <condition>Subcortical Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>Zydena (Udenafil)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zydena (Udenafil) 100 mg, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zydena (Udenafil)</intervention_name>
    <description>Zydena (Udenafil) 100 mg, one time</description>
    <arm_group_label>Zydena (Udenafil)</arm_group_label>
    <other_name>Zydena</other_name>
    <other_name>Udenafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        for Normal control group

          -  Normal cognition by detailed neuropsychological tests

          -  Brain MRI scan with no or minimal white matter hyperintensities

        for Subcortical vascular mild cognitive impairment (svMCI)

          -  Clinical diagnosis of svMCI

          -  Brain MRI scan with severe white matter hyperintensities

        Exclusion Criteria:

        - Contraindications to phosphodiesterase type 5 (Zydena, Udenafil)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk L. Na, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyunhee Jung, BSc</last_name>
    <phone>82-2-3410-6830</phone>
    <phone_ext>6830</phone_ext>
    <email>napapaya@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Duk L. Na, MD. PhD</last_name>
    <phone>82-2-3410-3599</phone>
    <phone_ext>3599</phone_ext>
    <email>dukna@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyunhee Jung, BSc</last_name>
      <phone>82-2-3410-6830</phone>
      <phone_ext>6830</phone_ext>
      <email>napapaya@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Duk Lyul Na</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Vascular dementia</keyword>
  <keyword>Subcortical vascular dementia</keyword>
  <keyword>Phosphodiesterase 5</keyword>
  <keyword>Udenafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

